Atara biotherapeutics to receive additional near-term milestone payment under updated tabelecleucel (tab-cel®) commercialization agreement with pierre fabre

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, today announced an update to its existing collaboration agreement with pierre fabre for the commercialization of tabelecleucel (tab-cel®) for epstein-barr virus (ebv)-positive cancers. under the amended terms, atara will receive an additional usd 30 million milestone payment upon tab-cel® ec approval and subsequent filing of the marketing authorization application (maa) tr
ATRA Ratings Summary
ATRA Quant Ranking